Racial Differences in Population Attributable Risk for Epithelial Ovarian Cancer in the OCWAA Consortium

Abstract

Background

The causes of racial disparities in epithelial ovarian cancer (EOC) incidence remain unclear. Differences in the prevalence of ovarian cancer risk factors may explain disparities in EOC incidence among African American (AA) and White women.

Methods

We used data from 4 case-control studies and 3 case-control studies nested within prospective cohorts in the Ovarian Cancer in Women of African Ancestry Consortium to estimate race-specific associations of 10 known or suspected EOC risk factors using logistic regression. Using the Bruzzi method, race-specific population attributable risks (PAR) were estimated for each risk factor individually and collectively, including groupings of exposures (reproductive factors and modifiable factors). All statistical tests were 2-sided.

Results

Among 3244 White EOC cases and 9638 controls and 1052 AA EOC cases and 2410 controls, AA women had a statistically significantly higher PAR (false discovery rate [FDR] P < .001) for first-degree family history of breast cancer (PAR = 10.1%, 95% confidence interval [CI] = 6.5% to 13.7%) compared with White women (PAR = 2.6%, 95% CI = 0.8% to 4.4%). After multiple test correction, AA women had a higher PAR than White women when evaluating all risk factors collectively (PAR = 61.6%, 95% CI = 48.6% to 71.3% vs PAR = 43.0%, 95% CI = 32.8% to 51.4%, respectively; FDR P = .06) and for modifiable exposures, including body mass index, oral contraceptives, aspirin, and body powder (PAR = 36.0%, 95% CI = 21.0% to 48.8% vs PAR = 13.8%, 95% CI = 4.5% to 21.8%, respectively; FDR P = .04).

Conclusions

Collectively, the selected risk factors accounted for slightly more of the risk among AA than White women, and interventions to reduce EOC incidence that are focused on multiple modifiable risk factors may be slightly more beneficial to AA women than White women at risk for EOC.

Funding

NCI NIH HHS

K01 CA212056

NCI NIH HHS

UM1 CA173642

NCI NIH HHS

U01 CA164974

NIA NIH HHS

HHSN271201100004C

NCI NIH HHS

R01 CA207260

NCI NIH HHS

U01 CA164973

NCI NIH HHS

R00 CA218681

NCI NIH HHS

U01 CA202979

National Cancer Institute

R01CA207260

National Institutes of Health

R01CA142081

AACES

R01CA058420

AACES

UM1CA164974

AACES

U01CA164974

BWHS

P60MD003424

CCCCS

N01CN025403

CCCCS

P01CA17054

CCCCS

P30CA14089

CCCCS

R01CA61132

CCCCS

N01PC67010

CCCCS

R03CA113148

CCCCS

R03CA115195

LACOCS

U01CA164973

MEC

R01CA76016

NCOCS

R01CA092447

NCOCS

U01CA202979

National Heart, Lung, and Blood Institute

National Institutes of Health

US Department of Health and Human Services

HHSN268201600001C

US Department of Health and Human Services

HHSN268201100046C

US Department of Health and Human Services

HHSN268201100001C

US Department of Health and Human Services

HHSN268201100002C

US Department of Health and Human Services

HHSN268201100003C

US Department of Health and Human Services

HHSN268201100004C

US Department of Health and Human Services

HHSN271201100004C

WHI Cancer Survivor Cohort

5UM1CA173642–05

National Cancer Institute

K22 CA193860

National Cancer Institute

R00 CA218681